A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

References

• Li X, Sridhar S, Chan JF. The Coronavirus disease 2019 pandemic: how does it spread and how do we stop it? Curr Opin HIV AIDS. 2020 Nov;15(6):328–335.
   Web of Science ®Google Scholar
• Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241536.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479–488.
   PubMed Web of Science ®Google Scholar
• Zhang N-N, Li X-F, Deng Y-Q, et al. A thermostable mRNA vaccine against COVID-19. Cell. 2020 Sep 3;182(5):1271–1283.e16.
   PubMed Web of Science ®Google Scholar
• Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020 Aug 14;11(1):4081.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARSCoV-2 induces protective immunity. Nature. 2020 Oct;586(7830):572–577.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 Oct;586(7830):567–571.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020 Aug;584(7821):450–456.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020 Sep 3;182(5):1295–1310e20.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020 Aug 20;182(4):812–827.e19.
   PubMed Web of Science ®Google Scholar
• Chibo D, Birch C. Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains. J Gen Virol. 2006 May;87(Pt 5):1203–1208.
   Google Scholar
• Ren L, Zhang Y, Li J, et al. Genetic drift of human coronavirus OC43 spike gene during adaptive evolution. Sci Rep. 2015 Jun 22;5:11451.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003 Oct 10;302(5643):276–278.
   PubMed Web of Science ®Google Scholar
• Song H-D, Tu C-C, Zhang G-W, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA. 2005 Feb 15;102(7):2430–2435.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Gibbs JS, Angel M, et al. Defining B cell immunodominance to viruses. Nat Immunol. 2017 Apr;18(4):456–463.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Yewdell JW. Understanding and manipulating viral immunity: antibody immunodominance enters center stage. Trends Immunol. 2018 Jul;39(7):549–561.
   PubMed Web of Science ®Google Scholar
• Zhang B-Z, Hu Y-F, Chen L-L, et al. Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients. Cell Res. 2020 Aug;30(8):702–704.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF-W, Yuen TT-T, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020 May 1;1(1):e14–e23.
   PubMedGoogle Scholar
• Yuan S, Wang R, Chan JF-W, et al. Metallodrug ranitidine bismuth citrate suppresses SARSCoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020 Nov;5(11):1439–1448.
   PubMed Web of Science ®Google Scholar
• Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020 Dec 3;71(9):2428–2446.
   PubMed Web of Science ®Google Scholar
• Zhang AJ, Lee AC, Chan JF, et al. Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis. 2020 Nov 20.
   Web of Science ®Google Scholar
• Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis. 2005 Jul;11(7):1016–1020.
   PubMed Web of Science ®Google Scholar
• Yong CY, Ong HK, Yeap SK, et al. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front Microbiol. 2019;10:1781.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park Y-J, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided highresolution serology. Cell. 2020 Nov 12;183(4):1024–1042 e21.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020 Jul 9;182(1):73–84.e16.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 Aug 21;369(6506):956–963.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 May 4;11(1):2251.
   PubMed Web of Science ®Google Scholar
• Du S, Cao Y, Zhu Q, et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell. 2020 Nov 12;183(4):1013–1023.e13.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Aug;584(7819):115–119.
   PubMed Web of Science ®Google Scholar
• Barnes CO, West AP, Jr, Huey-Tubman KE, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020 Aug 20;182(4):828–842.e16.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020 Jun 12;368(6496):1274–1278.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020 Aug 7;369(6504):643–650.
   PubMed Web of Science ®Google Scholar
• Kreye J, Reincke SM, Kornau H-C, et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020 Nov 12;183(4):1058–1069.e19.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu W, Xia S, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 Nov 27;5(1):282.
   PubMed Web of Science ®Google Scholar
• Lu S, Xie X-x, Zhao L, et al. The immunodominant and neutralization linear epitopes for SARS-CoV-2. bioRxiv. 2020 2020-01-01 00:00:00.
   Google Scholar
• Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020 Jun 1;11(1):2806.
   PubMed Web of Science ®Google Scholar
• Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Apr;176:104742.
   PubMed Web of Science ®Google Scholar